

Avita Medical to Present at the *2016 Cell & Gene Meeting on the Mesa* in California

Northridge, CA, Perth, Australia and London, United Kingdom - 5 October 2016 – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that Andrew Quick, Avita's Senior Vice President of Clinical Development will be presenting at the upcoming 2016 Cell & Gene Meeting on the Mesa being held October 5-7 in La Jolla, CA, USA.

The Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine and the Sanford Consortium for Regenerative Medicine, brings together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first event of its kind dedicated solely to facilitating connections in this sector.

Mr. Quick's presentation during the Partnering Forum will update audiences on Avita's scientific and clinical research developments, providing new data both on the mechanism of action of Regenerative Epithelial Suspension™ as well as clinical outcomes across the range of indications for which the Company's portfolio of products (ReCell®, ReGenerCell™ and ReNovaCell™) are in use around the world. Mr. Quick will also discuss Avita's work toward preparation for use of ReCell® as a medical countermeasure for US mass casualty preparedness with the Biomedical Advanced Research and Development Authority (BARDA).

Presentation details:

Date: Thursday, 6 October
Time: 3:30 p.m. Pacific Time
Location: La Jolla Ballroom 2, at the Estancia La Jolla Hotel, La Jolla, CA, USA.

Andrew Quick commented: "With over 800 attendees including researchers, clinicians, senior executives and decision-makers with industry experience to advance cutting-edge research into cures, we are able to connect with leading specialists in the field and present our exciting progress toward realising better outcomes for patients."

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION

Avita Medical Ltd Adam Kelliher Chief Executive Officer Phone: +44 (0) 1763 269 772 akelliher@avitamedical.com Avita Medical Ltd Tim Rooney Chief Financial Officer Phone: + 1 (818) 356-9400 trooney@avitamedical.com Avita Medical Ltd Gabriel Chiappini Company Secretary Phone +61(0) 8 9474 7738 gabriel@laurus.net.au	UK/EU Instinctif Partners Gemma Howe/Sue Charles Phone +44 (0)20 7866 7860 avitamedical@instinctif.com	Australia Monsoon Communications Dean Felton Phone: +61 3 9620 3333 Mobile: +61 (0) 411 698 499 deanf@monsoon.com.au
---	---	---